Streetbeat News

Price Targets

JAZZ

Needham analyst Ami Fadia has reiterated a 'Buy' rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and maintained a price target of $226.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:57 am

MGNI

Needham analyst Laura Martin has reiterated a 'Buy' rating on Magnite (NASDAQ:MGNI) and maintained a price target of $15.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:57 am

TTD

Needham analyst Laura Martin has reiterated a 'Buy' rating on Trade Desk (NASDAQ:TTD) and maintained a price target of $100.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:56 am

CYRX

Needham analyst David Saxon has maintained a 'Buy' rating on CryoPort (NASDAQ:CYRX), but lowered the price target from $30 to $21.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:55 am

MX

Needham analyst Rajvindra Gill has reiterated a 'Buy' rating on MagnaChip Semiconductor (NYSE:MX) and maintained a price target of $13.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:52 am

SSYS

Needham analyst James Ricchiuti has reiterated a 'Buy' rating on Stratasys (NASDAQ:SSYS) and maintained a price target of $19.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:51 am

AVDL

Needham analyst Ami Fadia has reiterated a 'Buy' rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a price target of $18.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:50 am

PAR

Needham analyst Mayank Tandon has reiterated a 'Buy' rating on PAR Technology (NYSE:PAR) and maintained a price target of $43.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:49 am

MDNA

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Medicenna Therapeutics (NASDAQ:MDNA) and maintained a price target of $2.5.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:46 am

HARP

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Harpoon Therapeutics (NASDAQ:HARP) and maintained a price target of $4.5.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:46 am